Inclusion Criteria:  Unilateral or bilateral, primary or secondary lymphoedema of the upper or lower limb  If cancer-related lymphoedema, approval for participation in study from oncological specialist (patient participation has to be discussed during Multidisciplinary Oncological Consult); approval if:  estimated cancer-related survival is ≥3 years oncological safety is guaranteed: for instance, time interval since radiotherapy/ chemotherapy is ≥3 months Lymphoedema stage 1 to 2b Objective diagnosis of lymphoedema: ≥ 5% volume difference OR ≥ 2 minor/ 1 major criteria on lymphoscintigraphy OR presence of IndoCyanineGreen (ICG) dermal backflow Score on Lymph-ICF questionnaire at screening: ≥ 25 / 100 (= moderate level of problems in functioning related to the development of lymphoedema) History of at least 6 months of decongestive lymphatic therapy (DLT) until minimal pitting Age ≥ 18 years  Exclusion Criteria:  Participants with history of liposuction, lymphovenous anastomosis, lymph node transfer Pregnant participants Severe obese participants: BMI>35 Estimated cancer-related survival is <3 years and oncological safety is not guaranteed (e.g. interval since radiotherapy/ chemotherapy is <3 months) In case of lower limb lymphoedema: presence of chronic venous insufficiency C4, C5, C6; deep venous thrombosis; post-thrombotic syndrome Allergy for ICG, iodine, penicillin and sulphonamides; increased activity of thyroid gland; benign tumour in thyroid; heparin use and severe renal insufficiency